0000021076 false 6/30 Q3 2022 0000021076 2021-07-01 2022-03-31 0000021076 2022-04-18 xbrli:shares 0000021076 2022-01-01 2022-03-31 iso4217:USD 0000021076 2021-01-01 2021-03-31 0000021076 2020-07-01 2021-03-31 iso4217:USD xbrli:shares 0000021076 2022-03-31 0000021076 2021-06-30 0000021076 2020-06-30 0000021076 2021-03-31 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 clx:entity 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 xbrli:pure 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-01 2020-09-30 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:VitaminsMineralsAndSupplementsMember clx:HealthAndWellnessMember 2021-01-01 2021-03-31 0000021076 clx:VitaminsMineralsAndSupplementsMember clx:HealthAndWellnessMember us-gaap:TrademarksMember 2021-01-01 2021-03-31 0000021076 us-gaap:OtherIntangibleAssetsMember clx:HealthAndWellnessMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember 2021-01-01 2021-03-31 0000021076 us-gaap:SeniorNotesMember 2021-11-01 2021-11-30 0000021076 us-gaap:SeniorNotesMember 2021-11-30 0000021076 clx:RevolvingCreditAgreementMaturesMarch2027Member us-gaap:RevolvingCreditFacilityMember 2022-03-25 0000021076 clx:RevolvingCreditAgreementMaturesNovember2024Member us-gaap:RevolvingCreditFacilityMember 2019-11-30 0000021076 2022-03-25 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-07-01 2022-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2022-03-31 0000021076 clx:SoybeanOilFuturesMember 2022-03-31 0000021076 clx:JetFuelSwapsMember 2022-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-06-30 0000021076 clx:SoybeanOilFuturesMember 2021-06-30 0000021076 clx:JetFuelSwapsMember 2021-06-30 0000021076 clx:PurchasesofInventoryMember us-gaap:ForeignExchangeContractMember 2022-03-31 0000021076 clx:PurchasesofInventoryMember us-gaap:ForeignExchangeContractMember 2021-06-30 0000021076 us-gaap:InterestRateContractMember 2021-07-01 2022-03-31 0000021076 us-gaap:InterestRateContractMember 2022-03-31 0000021076 us-gaap:InterestRateContractMember 2021-06-30 0000021076 us-gaap:CommodityContractMember 2022-01-01 2022-03-31 0000021076 us-gaap:CommodityContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:CommodityContractMember 2021-07-01 2022-03-31 0000021076 us-gaap:CommodityContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2021-07-01 2022-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:InterestRateContractMember 2022-01-01 2022-03-31 0000021076 us-gaap:InterestRateContractMember 2021-01-01 2021-03-31 0000021076 us-gaap:InterestRateContractMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommodityContractMember 2022-03-31 0000021076 us-gaap:CommodityContractMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:CommodityContractMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2022-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2022-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAssetsMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAssetsMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermDebtMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermDebtMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermDebtMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableCommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermDebtMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2022-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2022-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2021-06-30 0000021076 us-gaap:CommonStockMember 2020-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000021076 us-gaap:RetainedEarningsMember 2020-12-31 0000021076 us-gaap:TreasuryStockMember 2020-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000021076 us-gaap:NoncontrollingInterestMember 2020-12-31 0000021076 2020-12-31 0000021076 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000021076 us-gaap:RetainedEarningsMember 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-03-31 0000021076 us-gaap:CommonStockMember 2021-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000021076 us-gaap:RetainedEarningsMember 2021-12-31 0000021076 us-gaap:TreasuryStockMember 2021-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-12-31 0000021076 2021-12-31 0000021076 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000021076 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000021076 us-gaap:CommonStockMember 2022-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000021076 us-gaap:RetainedEarningsMember 2022-03-31 0000021076 us-gaap:TreasuryStockMember 2022-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2022-03-31 0000021076 us-gaap:CommonStockMember 2020-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-06-30 0000021076 us-gaap:TreasuryStockMember 2020-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-07-01 2021-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2021-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-03-31 0000021076 us-gaap:TreasuryStockMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2020-07-01 2021-03-31 0000021076 us-gaap:CommonStockMember 2021-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-06-30 0000021076 us-gaap:TreasuryStockMember 2021-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-07-01 2022-03-31 0000021076 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2022-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-03-31 0000021076 us-gaap:TreasuryStockMember 2021-07-01 2022-03-31 0000021076 2020-11-18 2020-11-18 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2022-01-01 2022-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2022-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2021-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2022-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-07-01 2022-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2022-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2021-01-01 2021-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2022-01-01 2022-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2020-07-01 2021-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2021-07-01 2022-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2022-01-01 2022-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2021-01-01 2021-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2021-07-01 2022-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2020-07-01 2021-03-31 0000021076 clx:RetirementIncomeMember country:US 2022-01-01 2022-03-31 0000021076 clx:RetirementIncomeMember country:US 2021-01-01 2021-03-31 0000021076 clx:RetirementIncomeMember country:US 2021-07-01 2022-03-31 0000021076 clx:RetirementIncomeMember country:US 2020-07-01 2021-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2022-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-07-01 2022-03-31 0000021076 clx:DickinsonCountyMichiganMatterMember 2022-03-31 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-07-01 2022-03-31 clx:reportableSegment 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2021-07-01 2022-03-31 0000021076 clx:HealthAndWellnessMember us-gaap:OperatingSegmentsMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:OperatingSegmentsMember 2021-07-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:OperatingSegmentsMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000021076 clx:LifestyleMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:OperatingSegmentsMember 2021-07-01 2022-03-31 0000021076 clx:LifestyleMember us-gaap:OperatingSegmentsMember 2020-07-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:OperatingSegmentsMember 2022-01-01 2022-03-31 0000021076 clx:InternationalMember us-gaap:OperatingSegmentsMember 2021-01-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:OperatingSegmentsMember 2021-07-01 2022-03-31 0000021076 clx:InternationalMember us-gaap:OperatingSegmentsMember 2020-07-01 2021-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2021-07-01 2022-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2020-07-01 2021-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-03-31 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:VitaminsMineralsAndSupplementsMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:HouseholdMember clx:BagsWrapsAndContainersMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember clx:CatLitterMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:HouseholdMember clx:CatLitterMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember clx:CatLitterMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:HouseholdMember clx:CatLitterMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:HouseholdMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember clx:FoodProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:LifestyleMember clx:FoodProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember clx:FoodProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:LifestyleMember clx:FoodProductsMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:NaturalPersonalCareMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember clx:WaterFiltrationMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:LifestyleMember clx:WaterFiltrationMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember clx:WaterFiltrationMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:LifestyleMember clx:WaterFiltrationMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:LifestyleMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 clx:InternationalMember us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2022-01-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-01-01 2021-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2021-07-01 2022-03-31 0000021076 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2020-07-01 2021-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

(Mark One) |  |
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022.
OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 1-07151
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)

Delaware | 31-0595760
(State or other jurisdiction of | (I.R.S. Employer Identification No.)
incorporation or organization) |

1221 Broadway, Oakland, California, 94612-1888
(Address of principal executive offices) (Zip code)
(510) 271-7000
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock - $1.00 par value | CLX | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Smaller Reporting Company | ☐ | Emerging Growth Company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of April 18, 2022, there were 123,079,993 shares outstanding of the registrant’s common stock ($1.00 par value).

1

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except per share data)

|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Net sales |  | $ | 1,809 |  |  | $ | 1,781 |  |  | $ | 5,306 |  |  | $ | 5,539 |
Cost of products sold |  |  | 1,160 |  |  |  | 1,007 |  |  |  | 3,429 |  |  |  | 3,008 |
Gross profit |  |  | 649 |  |  |  | 774 |  |  |  | 1,877 |  |  |  | 2,531 |
Selling and administrative expenses |  |  | 233 |  |  |  | 237 |  |  |  | 710 |  |  |  | 744 |
Advertising costs |  |  | 153 |  |  |  | 200 |  |  |  | 502 |  |  |  | 566 |
Research and development costs |  |  | 31 |  |  |  | 32 |  |  |  | 98 |  |  |  | 104 |
Goodwill, trademark and other asset impairments |  |  | — |  |  |  | 329 |  |  |  | — |  |  |  | 329 |
Interest expense |  |  | 21 |  |  |  | 25 |  |  |  | 69 |  |  |  | 74 |
Other (income) expense, net |  |  | 11 |  |  |  | 10 |  |  |  | 20 |  |  |  | (85) |
Earnings (losses) before income taxes |  |  | 200 |  |  |  | (59) |  |  |  | 478 |  |  |  | 799 |
Income taxes |  |  | 48 |  |  |  | — |  |  |  | 111 |  |  |  | 180 |
Net earnings (losses) |  |  | 152 |  |  |  | (59) |  |  |  | 367 |  |  |  | 619 |
Less: Net earnings attributable to noncontrolling interests |  |  | 2 |  |  | 2 |  |  |  | 6 |  |  |  | 6 |
Net earnings (losses) attributable to Clorox |  | $ | 150 |  |  | $ | (61) |  |  | $ | 361 |  |  | $ | 613 |
Net earnings (losses) per share attributable to Clorox |  |  |  |  |  |  |  |  |  |  |  |
Basic net earnings (losses) per share |  | $ | 1.22 |  |  | $ | (0.49) |  |  | $ | 2.93 |  |  | $ | 4.86 |
Diluted net earnings (losses) per share |  | $ | 1.21 |  |  | $ | (0.49) |  |  | $ | 2.91 |  |  | $ | 4.78 |
Weighted average shares outstanding (in thousands) |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 123,177 |  |  |  | 125,610 |  |  |  | 123,074 |  |  |  | 126,057 |
Diluted |  |  | 123,877 |  |  |  | 125,610 |  |  |  | 123,943 |  |  |  | 128,030 |
Comprehensive income (loss) |  | $ | 207 |  |  | $ | (37) |  |  | $ | 394 |  |  | $ | 706 |
Less: Total comprehensive income attributable to noncontrolling interests |  |  | 2 |  |  | 2 |  |  |  | 6 |  |  |  | 6 |
Total comprehensive income (loss) attributable to Clorox |  | $ | 205 |  |  | $ | (39) |  |  | $ | 388 |  |  | $ | 700 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
2

The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except per share data)

| 3/31/2022 |  | 6/30/2021
| (Unaudited) |  |  |
ASSETS |  |  |  |  |
Current assets |  |  |  |  |
Cash and cash equivalents | $ | 241 |  |  | $ | 319 |
Receivables, net |  | 660 |  |  |  | 604 |
Inventories, net |  | 803 |  |  |  | 752 |
Prepaid expenses and other current assets |  | 165 |  |  |  | 154 |
Total current assets |  | 1,869 |  |  |  | 1,829 |
Property, plant and equipment, net of accumulated depreciation and amortization of $2,510 and $2,382, respectively |  | 1,312 |  |  |  | 1,302 |
Operating lease right-of-use assets |  | 311 |  |  |  | 332 |
Goodwill |  | 1,572 |  |  |  | 1,575 |
Trademarks, net |  | 690 |  |  |  | 693 |
Other intangible assets, net |  | 204 |  |  |  | 225 |
Other assets |  | 364 |  |  |  | 378 |
Total assets | $ | 6,322 |  |  | $ | 6,334 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |
Current liabilities |  |  |  |  |
Notes and loans payable | $ | 395 |  |  | $ | — |
Current maturities of long-term debt |  | 600 |  |  |  | 300 |
Current operating lease liabilities |  | 73 |  |  |  | 81 |
Accounts payable and accrued liabilities |  | 1,575 |  |  |  | 1,675 |
Total current liabilities |  | 2,643 |  |  |  | 2,056 |
Long-term debt |  | 1,887 |  |  |  | 2,484 |
Long-term operating lease liabilities |  | 288 |  |  |  | 301 |
Other liabilities |  | 843 |  |  |  | 834 |
Deferred income taxes |  | 85 |  |  |  | 67 |
Total liabilities |  | 5,746 |  |  |  | 5,742 |
Commitments and contingencies |  |  |  |  |
Stockholders’ equity |  |  |  |  |
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding |  | — |  |  |  | — |
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of March 31, 2022 and June 30, 2021; and 123,071,356 and 122,780,220 shares outstanding as of March 31, 2022 and June 30, 2021, respectively |  | 131 |  |  |  | 131 |
Additional paid-in capital |  | 1,195 |  |  |  | 1,186 |
Retained earnings |  | 951 |  |  |  | 1,036 |
Treasury stock, at cost: 7,670,105 and 7,961,241 shares as of March 31, 2022 and June 30, 2021, respectively |  | (1,358) |  |  |  | (1,396) |
Accumulated other comprehensive net (loss) income |  | (519) |  |  |  | (546) |
Total Clorox stockholders’ equity |  | 400 |  |  |  | 411 |
Noncontrolling interests |  | 176 |  |  |  | 181 |
Total stockholders’ equity |  | 576 |  |  |  | 592 |
Total liabilities and stockholders’ equity | $ | 6,322 |  |  | $ | 6,334 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
3

The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)

| Nine Months Ended
| 3/31/2022 |  | 3/31/2021
Operating activities: |  |  |  |  |
Net earnings | $ | 367 |  |  | $ | 619 |
Adjustments to reconcile net earnings to net cash provided by operations: |  |  |  |  |
Depreciation and amortization |  | 167 |  |  |  | 157 |
Stock-based compensation |  | 44 |  |  |  | 52 |
Deferred income taxes |  | 11 |  |  |  | (21) |
Goodwill, trademark and other asset impairments |  | — |  |  |  | 329 |
Other |  | 7 |  |  |  | (53) |
Changes in: |  |  |  |  |
Receivables, net |  | (56) |  |  |  | 46 |
Inventories, net |  | (53) |  |  |  | (220) |
Prepaid expenses and other current assets |  | 2 |  |  |  | (29) |
Accounts payable and accrued liabilities |  | (93) |  |  |  | 94 |
Operating lease right-of-use assets and liabilities, net |  | — |  |  |  | (1) |
Income taxes payable / prepaid |  | 55 |  |  |  | (80) |
Net cash provided by operations |  | 451 |  |  |  | 893 |
Investing activities: |  |  |  |  |
Capital expenditures |  | (172) |  |  |  | (232) |
Businesses acquired, net of cash acquired |  | — |  |  |  | (85) |
Other |  | 5 |  |  |  | (24) |
Net cash used for investing activities |  | (167) |  |  |  | (341) |
Financing activities: |  |  |  |  |
Notes and loans payable, net |  | 395 |  |  |  | — |
Long-term debt repayments |  | (300) |  |  |  | — |
Treasury stock purchased |  | (25) |  |  |  | (605) |
Cash dividends paid to Clorox stockholders |  | (428) |  |  |  | (420) |
Cash dividends paid to noncontrolling interests |  | (5) |  |  |  | (18) |
Issuance of common stock for employee stock plans and other |  | — |  |  |  | 99 |
Net cash used for financing activities |  | (363) |  |  |  | (944) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash |  | (2) |  |  |  | 10 |
Net increase (decrease) in cash, cash equivalents, and restricted cash |  | (81) |  |  |  | (382) |
Cash, cash equivalents, and restricted cash: |  |  |  |  |
Beginning of period |  | 324 |  |  |  | 879 |
End of period | $ | 243 |  |  | $ | 497 |

See Notes to Condensed Consolidated Financial Statements (Unaudited)
4

The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2022 and 2021, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Adopted Accounting Standards
In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.
NOTE 2. BUSINESS ACQUIRED
Saudi Joint Venture Acquisition
On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture) from 30 percent to 51 percent. The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. With the additional investment, the Company has consolidated this joint venture into its consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests. As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, noncash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021.
The Saudi joint venture acquisition was accounted for under the acquisition method of accounting for business combinations. The total purchase consideration was $111 consisting of $100 cash paid and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date. The fair value of the total net assets and noncontrolling interests recorded as of the date of acquisition was $412 and $198, respectively. The purchase price allocation was finalized during the second quarter of fiscal year 2021.
Refer to the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 for the final purchase price allocation, valuation methodology and other information related to the Saudi joint venture acquisition.
5

NOTE 3. INVENTORIES, NET
Inventories, net, consisted of the following as of:

| 3/31/2022 |  | 6/30/2021
Finished goods | $ | 602 |  |  | $ | 543 |
Raw materials and packaging | 206 |  |  | 229 |
Work in process | 37 |  |  | 11 |
LIFO allowances | (42) |  |  | (31) |
Total | $ | 803 |  |  | $ | 752 |

NOTE 4. GOODWILL, TRADEMARK AND OTHER ASSET IMPAIRMENTS
The Company tests its goodwill and other indefinite-lived intangible assets for impairment annually in the fiscal fourth quarter unless there are indications during a different interim period that these assets may have become impaired. Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying value of an asset (or asset group) may not be recoverable.
There were no impairment charges for goodwill or intangible assets recorded by the Company during the three and nine months ended March 31, 2022.
During the third quarter of fiscal 2021, as a result of lower than expected actual and projected net sales growth and operating performance for the Vitamins, Minerals and Supplements (VMS) strategic business unit (SBU), a strategic review was initiated by management that resulted in updated financial and operational plans. These events were considered a triggering event requiring interim impairment assessments to be performed on the VMS reporting unit, indefinite-lived trademarks and other assets. Based on the outcome of these assessments, the following pre-tax impairment charges were recorded:

| Impairment Charge
Goodwill | $ | 228 |
Trademarks, net | 93 |
Other intangible assets, net | 7 |
Property, plant and equipment, net | 1 |
Total | $ | 329 |

In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of $62 due to the partial tax deductibility of these charges.
Refer to the Notes to Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2021 for further information related to the VMS reporting unit goodwill, intangibles and other asset impairments.
NOTE 5. DEBT
Short-term borrowings
In November 2021, $300 of the Company’s senior notes with an annual fixed interest rate of 3.80% became due and were repaid using commercial paper borrowings.
The weighted average effective interest rate of notes and loans payable as of March 31, 2022 was 0.77%. The Company had no notes and loans payable outstanding as of June 30, 2021.
6

NOTE 5: DEBT (continued)
Credit arrangements
On March 25, 2022, the Company entered into a new $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2027. The Credit Agreement replaced a prior $1,200 revolving credit agreement (the Prior Credit Agreement) in place since November 2019. The Credit Agreement changed the interest rate benchmark used as a reference rate for borrowings under the Credit Agreement from the London Interbank Offered Rate (LIBOR) to the secured overnight financing rate (SOFR). The Company did not incur any termination fees or penalties in connection with entering the new agreement, which was considered a debt modification. There were no borrowings under either the Credit Agreement or the Prior Credit Agreement as of March 31, 2022 and June 30, 2021, respectively, and the Company believes that borrowings under the new Credit Agreement will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations consistent with the previous agreement, with which the Company was in compliance as of March 31, 2022.
NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments
The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.
Commodity Price Risk Management
The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.
As of March 31, 2022, the notional amount of commodity derivatives was $25, of which $13 r elated to soybean oil futures used for the Food products busines s and $12 related to jet fuel swaps used for the Grilling business. As of June 30, 2021, the notional amount of commodity derivatives was $32, of which $23 related to soybean oil futures and $9 related to jet fuel swaps.
Foreign Currency Risk Management
The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.
The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $59 and $70, respectively, as of March 31, 2022 and June 30, 2021.
Interest Rate Risk Management
The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.
The notional amounts of outstanding interest rate contracts used by the Company were $950 and $300, respectively, as of March 31, 2022 and June 30, 2021. These contracts represent interest rate swap lock agreements to manage the exposure to interest rate volatility associated with future interest payments on forecasted debt issuance.
Commodity, Foreign Exchange and Interest Rate Derivatives
The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.
7

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings (loss) were as follows:

| Gains (losses) recognized in Other comprehensive (loss) income
| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Commodity purchase derivative contracts | $ | 10 |  |  | $ | 5 |  |  | $ | 12 |  |  | $ | 12 |
Foreign exchange derivative contracts | (1) |  |  | 2 |  |  | — |  |  | (1) |
Interest rate derivative contracts | 39 |  |  | 26 |  |  | 39 |  |  | 36 |
Total | $ | 48 |  |  | $ | 33 |  |  | $ | 51 |  |  | $ | 47 |

| Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings (losses) | Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (losses)
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Commodity purchase derivative contracts | Cost of products sold | $ | 3 |  |  | $ | — |  |  | $ | 13 |  |  | $ | (2) |
Foreign exchange derivative contracts | Cost of products sold | — |  |  | — |  |  | — |  |  | — |
Interest rate derivative contracts | Interest expense | — |  |  | (2) |  |  | (3) |  |  | (5) |
Total |  | $ | 3 |  |  | $ | (2) |  |  | $ | 10 |  |  | $ | (7) |

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2022 that is expected to be reclassified into Net earnings (losses) within the next twelve months is $12.
Counterparty Risk Management and Derivative Contract Requirements
The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of both March 31, 2022 and June 30, 2021, $0 contained such terms. As of both March 31, 2022 and June 30, 2021, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.
Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2022 and June 30, 2021, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.
Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of both March 31, 2022 and June 30, 2021, the Company maintained cash margin balances related to exchange-traded futures contracts of $0, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.
8

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Trust Assets
The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.
Fair Value of Financial Instruments
Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:
Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.
As of both March 31, 2022 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:

|  |  |  |  | 3/31/2022 |  | 6/30/2021
| Balance Sheet Classification |  | Fair Value Hierarchy Level |  | Carrying Amount |  | Estimated Fair Value |  | Carrying Amount |  | Estimated Fair Value
Assets |  |  |  |  |  |  |  |  |  |  |
Commodity purchase futures contracts | Prepaid expenses and other current assets |  | 1 |  | $ | 1 |  |  | $ | 1 |  |  | $ | 5 |  |  | $ | 5 |
Commodity purchase swaps contracts | Prepaid expenses and other current assets |  | 2 |  | 6 |  |  | 6 |  |  | 4 |  |  | 4 |
Commodity purchase swaps contracts | Other assets |  | 2 |  | 1 |  |  | 1 |  |  | — |  |  | — |
Interest rate contracts | Prepaid expenses and other current assets |  | 2 |  | 63 |  |  | 63 |  |  | 24 |  |  | 24 |
|  |  |  |  | $ | 71 |  |  | $ | 71 |  |  | $ | 33 |  |  | $ | 33 |

9

NOTE 6. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:

|  |  |  |  | 3/31/2022 |  | 6/30/2021
| Balance Sheet Classification |  | Fair Value Hierarchy Level |  | Carrying Amount |  | Estimated Fair Value |  | Carrying Amount |  | Estimated Fair Value
Assets |  |  |  |  |  |  |  |  |  |  |
Interest-bearing investments, including money market funds | Cash and cash equivalents (1) |  | 1 |  | $ | 101 |  |  | $ | 101 |  |  | $ | 196 |  |  | $ | 196 |
Time deposits | Cash and cash equivalents (1) |  | 2 |  | 7 |  |  | 7 |  |  | 11 |  |  | 11 |
Trust assets for nonqualified deferred compensation plans | Other assets |  | 1 |  | 134 |  |  | 134 |  |  | 136 |  |  | 136 |
|  |  |  |  | $ | 242 |  |  | $ | 242 |  |  | $ | 343 |  |  | $ | 343 |
Liabilities |  |  |  |  |  |  |  |  |  |  |
Notes and loans payable | Notes and loans payable (2) |  | 2 |  | $ | 395 |  |  | $ | 395 |  |  | $ | — |  |  | $ | — |
Current maturities of long-term debt and Long-term debt | Current maturities of long- term debt and Long-term debt (3) |  | 2 |  | 2,487 |  |  | 2,461 |  |  | 2,784 |  |  | 2,963 |
|  |  |  |  | $ | 2,882 |  |  | $ | 2,856 |  |  | $ | 2,784 |  |  | $ | 2,963 |

(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.
(3)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
NOTE 7. INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings (losses) was 23.9% and 23.3% for the three and nine months ended March 31, 2022, respectively, and (1.4)% and 22.5% for the three and nine months ended March 31, 2021, respectively. The substantially lower tax rate on losses before income taxes in the prior three month period was driven by the partial non-deductibility of impaired VMS goodwill.
NOTE 8. NET EARNINGS (LOSSES) PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Basic | 123,177 |  | 125,610 |  | 123,074 |  | 126,057
Dilutive effect of stock options and other | 700 |  | — |  | 869 |  | 1,973
Diluted | 123,877 |  | 125,610 |  | 123,943 |  | 128,030
Antidilutive stock options and other | 2,489 |  | 4,826 |  |  | 2,489 |  |  | 428 |

Basic net earnings (losses) per share and Diluted net earnings (losses) per share are calculated on Net earnings (losses) attributable to Clorox.
Since the Company generated net losses attributable to Clorox for the three months ended March 31, 2021, there was no dilutive effect of stock options and other instruments because their impact would be antidilutive.
10

NOTE 9. COMPREHENSIVE INCOME (LOSS)
The following table provides a summary of Comprehensive income (loss) for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Net earnings (losses) | $ | 152 |  |  | $ | (59) |  |  | $ | 367 |  |  | $ | 619 |
Other comprehensive (loss) income, net of tax: |  |  |  |  |  |  |
Foreign currency translation adjustments | 19 |  |  | (7) |  |  | (9) |  |  | 40 |
Net unrealized gains (losses) on derivatives | 34 |  |  | 27 |  |  | 31 |  |  | 42 |
Pension and postretirement benefit adjustments | 2 |  |  | 2 |  |  | 5 |  |  | 5 |
Total other comprehensive (loss) income, net of tax | 55 |  |  | 22 |  |  | 27 |  |  | 87 |
Comprehensive income (loss) | 207 |  |  | (37) |  |  | 394 |  |  | 706 |
Less: Total comprehensive income attributable to noncontrolling interests | 2 |  |  | 2 |  |  | 6 |  |  | 6 |
Total comprehensive income (loss) attributable to Clorox | $ | 205 |  |  | $ | (39) |  |  | $ | 388 |  |  | $ | 700 |

11

NOTE 10. STOCKHOLDERS’ EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:

| Three Months Ended March 31
(Dollars in millions except per share data; shares in thousands) | Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | Treasury Stock |  | Accumulated Other Comprehensive Net (Loss) Income |  | Non-controlling interests |  | Total Stockholders’ Equity
Amount |  | Shares |  |  |  | Amount |  | Shares |  |  |
Balance as of December 31, 2020 | $ | 131 |  |  | 130,741 |  |  | $ | 1,176 |  |  | $ | 1,302 |  |  | $ | (850) |  |  | (5,017) |  |  | $ | (575) |  |  | $ | 196 |  |  | $ | 1,380 |
Net earnings (losses) | — |  |  | — |  |  | — |  |  | (61) |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | (59) |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 22 |  |  | — |  |  | 22 |
Dividends to Clorox stockholders ($1.11 per share declared) | — |  |  | — |  |  | — |  |  | (139) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (139) |
Dividends to non-controlling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (3) |  |  | (3) |
Stock-based compensation | — |  |  | — |  |  | 17 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 17 |
Other employee stock plan activities | — |  |  | — |  |  | (3) |  |  | (16) |  |  | 44 |  |  | 283 |  |  | — |  |  | — |  |  | 25 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (305) |  |  | (1,648) |  |  | — |  |  | — |  |  | (305) |
Balance as of March 31, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,190 |  |  | $ | 1,086 |  |  | $ | (1,111) |  |  | (6,382) |  |  | $ | (553) |  |  | $ | 195 |  |  | $ | 938 |
Balance as of December 31, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,180 |  |  | $ | 949 |  |  | $ | (1,373) |  |  | (7,777) |  |  | $ | (574) |  |  | $ | 178 |  |  | $ | 491 |
Net earnings | — |  |  | — |  |  | — |  |  | 150 |  |  | — |  |  | — |  |  | — |  |  | 2 |  |  | 152 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 55 |  |  | — |  |  | 55 |
Dividends to Clorox stockholders ($1.16 per share declared) | — |  |  | — |  |  | — |  |  | (143) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (143) |
Dividends to non-controlling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (4) |  |  | (4) |
Stock-based compensation | — |  |  | — |  |  | 19 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 19 |
Other employee stock plan activities | — |  |  | — |  |  | (4) |  |  | (5) |  |  | 15 |  |  | 107 |  |  | — |  |  | — |  |  | 6 |
Balance as of March 31, 2022 | $ | 131 |  |  | 130,741 |  |  | $ | 1,195 |  |  | $ | 951 |  |  | $ | (1,358) |  |  | (7,670) |  |  | $ | (519) |  |  | $ | 176 |  |  | $ | 576 |

12

NOTE 10. STOCKHOLDERS’ EQUITY (Continued)

| Nine Months Ended March 31
(Dollars in millions except per share data; shares in thousands) | Common Stock |  | Additional Paid-in Capital |  | Retained Earnings |  | Treasury Stock |  | Accumulated Other Comprehensive Net (Loss) Income |  | Non-controlling interests |  | Total Stockholders’ Equity
Amount |  | Shares |  |  |  | Amount |  | Shares |  |  |
Balance as of June 30, 2020 | $ | 159 |  |  | 158,741 |  |  | $ | 1,137 |  |  | $ | 3,567 |  |  | $ | (3,315) |  |  | (32,543) |  |  | $ | (640) |  |  | $ | — |  |  | $ | 908 |
Net earnings | — |  |  | — |  |  | — |  |  | 613 |  |  | — |  |  | — |  |  | — |  |  | 6 |  |  | 619 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 87 |  |  | — |  |  | 87 |
Dividends to Clorox stockholders ($3.33 per share declared) | — |  |  | — |  |  | — |  |  | (421) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (421) |
Dividends to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (9) |  |  | (9) |
Business combinations including purchase accounting adjustments | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 198 |  |  | 198 |
Stock-based compensation | — |  |  | — |  |  | 52 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 52 |
Other employee stock plan activities | — |  |  | — |  |  | 1 |  |  | (33) |  |  | 141 |  |  | 1,233 |  |  | — |  |  | — |  |  | 109 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (605) |  |  | (3,072) |  |  | — |  |  | — |  |  | (605) |
Treasury stock retirement (1) | (28) |  |  | (28,000) |  |  | — |  |  | (2,640) |  |  | 2,668 |  |  | 28,000 |  | $ | — |  |  | — |  |  | — |
Balance as of March 31, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,190 |  |  | $ | 1,086 |  |  | $ | (1,111) |  |  | (6,382) |  |  | $ | (553) |  |  | $ | 195 |  |  | $ | 938 |
Balance as of June 30, 2021 | $ | 131 |  |  | 130,741 |  |  | $ | 1,186 |  |  | $ | 1,036 |  |  | $ | (1,396) |  |  | (7,961) |  |  | $ | (546) |  |  | $ | 181 |  |  | $ | 592 |
Net earnings | — |  |  | — |  |  | — |  |  | 361 |  |  | — |  |  | — |  |  | — |  |  | 6 |  |  | 367 |
Other comprehensive (loss) income | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 27 |  |  | — |  |  | 27 |
Dividends to Clorox stockholders ($3.48 per share declared) | — |  |  | — |  |  | — |  |  | (430) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (430) |
Dividends to noncontrolling interests | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (11) |  |  | (11) |
Stock-based compensation | — |  |  | — |  |  | 44 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 44 |
Other employee stock plan activities | — |  |  | — |  |  | (35) |  |  | (16) |  |  | 63 |  |  | 443 |  |  | — |  |  | — |  |  | 12 |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | — |  |  | (25) |  |  | (152) |  |  | — |  |  | — |  |  | (25) |
Balance as of March 31, 2022 | $ | 131 |  |  | 130,741 |  |  | $ | 1,195 |  |  | $ | 951 |  |  | $ | (1,358) |  |  | (7,670) |  |  | $ | (519) |  |  | $ | 176 |  |  | $ | 576 |

(1) On November 18, 2020 the Company retired 28 million shares of its treasury stock. These shares are now authorized but unissued. There was no effect on the Company’s overall equity position as a result of the retirement.
13

NOTE 10. STOCKHOLDERS’ EQUITY (Continued)
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:

| Three Months Ended March 31
| Foreign currency translation adjustments |  | Net unrealized gains (losses) on derivatives |  | Pension and postretirement benefit adjustments |  | Accumulated other comprehensive net (loss) income
Balance as of December 31, 2020 | $ | (403) |  |  | $ | (3) |  |  | $ | (169) |  |  | $ | (575) |
Other comprehensive (loss) income before reclassifications | (6) |  |  | 33 |  |  | — |  |  | 27 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 2 |  |  | 3 |  |  | 5 |
Income tax benefit (expense) | (1) |  |  | (8) |  |  | (1) |  |  | (10) |
Net current period other comprehensive (loss) income | (7) |  |  | 27 |  |  | 2 |  |  | 22 |
Balance as of March 31, 2021 | $ | (410) |  |  | $ | 24 |  |  | $ | (167) |  |  | $ | (553) |
Balance as of December 31, 2021 | $ | (431) |  |  | $ | 18 |  |  | $ | (161) |  |  | $ | (574) |
Other comprehensive (loss) income before reclassifications | 19 |  |  | 48 |  |  | — |  |  | 67 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | (3) |  |  | 2 |  |  | (1) |
Income tax benefit (expense), and other | — |  |  | (11) |  |  | — |  |  | (11) |
Net current period other comprehensive (loss) income | 19 |  |  | 34 |  |  | 2 |  |  | 55 |
Balance as of March 31, 2022 | $ | (412) |  |  | $ | 52 |  |  | $ | (159) |  |  | $ | (519) |
| Nine Months Ended March 31
| Foreign currency translation adjustments |  | Net unrealized gains (losses) on derivatives |  | Pension and postretirement benefit adjustments |  | Accumulated other comprehensive net (loss) income
Balance as of June 30, 2020 | $ | (450) |  |  | $ | (18) |  |  | $ | (172) |  |  | $ | (640) |
Other comprehensive (loss) income before reclassifications | 38 |  |  | 47 |  |  | — |  |  | 85 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | 7 |  |  | 7 |  |  | 14 |
Income tax benefit (expense) | 2 |  |  | (12) |  |  | (2) |  |  | (12) |
Net current period other comprehensive (loss) income | 40 |  |  | 42 |  |  | 5 |  |  | 87 |
Balance as of March 31, 2021 | $ | (410) |  |  | $ | 24 |  |  | $ | (167) |  |  | $ | (553) |
Balance as of June 30, 2021 | $ | (403) |  |  | $ | 21 |  |  | $ | (164) |  |  | $ | (546) |
Other comprehensive (loss) income before reclassifications | (9) |  |  | 51 |  |  | — |  |  | 42 |
Amounts reclassified from Accumulated other comprehensive net (loss) income | — |  |  | (10) |  |  | 6 |  |  | (4) |
Income tax benefit (expense), and other | — |  |  | (10) |  |  | (1) |  |  | (11) |
Net current period other comprehensive (loss) income | (9) |  |  | 31 |  |  | 5 |  |  | 27 |
Balance as of March 31, 2022 | $ | (412) |  |  | $ | 52 |  |  | $ | (159) |  |  | $ | (519) |

Included in foreign currency translation adjustments are remeasurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
14

NOTE 11. EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Service cost | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Interest cost | 3 |  |  | 4 |  |  | 11 |  |  | 11 |
Expected return on plan assets (1) | (4) |  |  | (4) |  |  | (11) |  |  | (11) |
Settlement loss recognized | 1 |  |  | — |  |  | 1 |  |  | — |
Amortization of unrecognized items | 3 |  |  | 3 |  |  | 7 |  |  | 8 |
Total | $ | 3 |  |  | $ | 3 |  |  | $ | 8 |  |  | $ | 8 |

(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three and nine months ended March 31, 2022, and $0 and $(1) for the three and nine months ended March 31, 2021, respectively.
During the three months ended March 31, 2022 and 2021, the Company made $8 and $6 in contributions to its domestic retirement income plans, respectively. During the nine months ended March 31, 2022 and 2021, the Company made $13 and $10 in contributions to its domestic retirement income plans, respectively.
Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs, all other components are reflected in Other (income) expense, net.
NOTE 12. OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both March 31, 2022 and June 30, 2021, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of both March 31, 2022 and June 30, 2021, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. Following further discussions with the regulators in 2017, the Company recorded an undiscounted liability for costs estimated to be incurred over a 30-year period, based on one of the options in the Feasibility Study. In September 2021, as a result of an additional study and further discussions with regulators, the Company submitted a Soil Vapor Intrusion Report to the regulators, which has not resulted in a change to the recorded liability. While the Company believes its latest estimates of remediation costs are reasonable, the ultimate remediation requirements are not yet finalized and the regulators could require the Company to implement remediation actions for a longer period or take additional actions, which could include estimated undiscounted costs of up to approximately $28 over an estimated 30-year period, or require the Company to take different actions and incur additional costs.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $9 and $10 of the recorded liability, as of March 31, 2022 and June 30, 2021, respectively. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time.
15

NOTE 12: OTHER CONTINGENCIES AND GUARANTEES (continued)
The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies. The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of both March 31, 2022 and June 30, 2021.
As of March 31, 2022, the Company was party to a letter of credit of $14, related to one of its insurance carriers, of which $0 had been drawn upon.
16

NOTE 13. SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings (losses) before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.

|  | Net sales
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Health and Wellness |  | $ | 662 |  |  | $ | 680 |  |  | $ | 2,055 |  |  | $ | 2,310 |
Household |  | 539 |  |  | 510 |  |  | 1,404 |  |  | 1,421 |
Lifestyle |  | 306 |  |  | 293 |  |  | 961 |  |  | 928 |
International |  | 302 |  |  | 298 |  |  | 886 |  |  | 880 |
Total |  | $ | 1,809 |  |  | $ | 1,781 |  |  | $ | 5,306 |  |  | $ | 5,539 |
|  | Earnings (losses) before income taxes
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Health and Wellness (1) |  | $ | 84 |  |  | $ | (183) |  |  | $ | 245 |  |  | $ | 315 |
Household |  | 92 |  |  | 97 |  |  | 138 |  |  | 266 |
Lifestyle |  | 66 |  |  | 68 |  |  | 239 |  |  | 259 |
International |  | 31 |  |  | 30 |  |  | 80 |  |  | 184 |
Corporate |  | (73) |  |  | (71) |  |  | (224) |  |  | (225) |
Total |  | $ | 200 |  |  | $ | (59) |  |  | $ | 478 |  |  | $ | 799 |

(1) The earnings (losses) before income taxes for the Health and Wellness segment include a $329 non-cash goodwill, trademark and other asset impairment charge for the VMS SBU for the three and nine months ended March 31, 2021.
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% for the three and nine months ended March 31, 2022, and 24% for the three and nine months ended March 31, 2021.
17

NOTE 13. SEGMENT RESULTS (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:

|  | Net sales |
|  | Three Months Ended |  | Nine Months Ended
|  | 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Cleaning |  | 28 |  | % |  | 29 |  | % |  | 30 |  | % |  | 30 |  | %
Professional Products |  | 4 |  |  |  | 5 |  |  |  | 5 |  |  |  | 7 |  |
Vitamins, Minerals and Supplements |  | 4 |  |  |  | 4 |  |  |  | 4 |  |  |  | 4 |  |
Health and Wellness |  | 36 |  | % |  | 38 |  | % |  | 39 |  | % |  | 41 |  | %
Bags and Wraps |  | 12 |  |  |  | 11 |  |  |  | 12 |  |  |  | 11 |  |
Cat Litter |  | 8 |  |  |  | 7 |  |  |  | 8 |  |  |  | 7 |  |
Grilling |  | 10 |  |  |  | 11 |  |  |  | 6 |  |  |  | 8 |  |
Household |  | 30 |  | % |  | 29 |  | % |  | 26 |  | % |  | 26 |  | %
Food Products |  | 10 |  |  |  | 10 |  |  |  | 10 |  |  |  | 9 |  |
Natural Personal Care |  | 4 |  |  |  | 3 |  |  |  | 4 |  |  |  | 4 |  |
Water Filtration |  | 3 |  |  |  | 3 |  |  |  | 4 |  |  |  | 4 |  |
Lifestyle |  | 17 |  | % |  | 16 |  | % |  | 18 |  | % |  | 17 |  | %
International |  | 17 |  | % |  | 17 |  | % |  | 17 |  | % |  | 16 |  | %
Total |  | 100 |  | % |  | 100 |  | % |  | 100 |  | % |  | 100 |  | %

18

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The Clorox Company
(Dollars in millions, except per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, which was filed with the SEC on August 10, 2021, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three and nine month periods ended March 31, 2022 (the current period) to the three and nine month periods ended March 31, 2021 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.
EXECUTIVE OVERVIEW
Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 9,000 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings, dips, seasonings and sauces; Brita® water-filtration systems and filters; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality® and NeoCell® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and Clorox Healthcare® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.
The Company operates through strategic business units (SBUs) which are also the Company’s operating segments. These SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. These four reportable segments consist of the following:
•Health and Wellness consists of cleaning products, professional products and vitamins, minerals and supplement products mainly marketed and sold in the U.S. Products within this segment include cleaning products such as laundry additives and home care products, primarily under the Clorox®, Clorox2®, Scentiva®, Pine-Sol®, Liquid-Plumr®, Tilex® and Formula 409® brands; professional cleaning and disinfecting products under the CloroxPro™, Clorox Healthcare® and Clorox® TurboPro TM brands; professional food service products under the Hidden Valley® brand; and vitamins, minerals and supplement products under the RenewLife®, Natural Vitality®, NeoCell® and Rainbow Light® brands.
•Household consists of cat litter products, bags and wraps and grilling products marketed and sold in the U.S. Products within this segment include cat litter products under the Fresh Step®, Scoop Away® and Ever Clean® brands; bags and wraps under the Glad® brand; and grilling products under the Kingsford® brand.
•Lifestyle consists of food, natural personal care products and water-filtration marketed and sold in the U.S. Products within this segment include dressings, dips, seasonings and sauces, primarily under the Hidden Valley® brand; natural personal care products under the Burt’s Bees® brand; and water-filtration systems and filters under the Brita® brand.
•International consists of products sold outside the U.S. Products within this segment include laundry additives, home care products, water-filtration systems and filters, digestive health products; grilling products; cat litter products; food products, bags and wraps, natural personal care products, and professional cleaning and disinfecting products marketed primarily under the Clorox®, Ayudin®, Clorinda®, Poett®, Pine-Sol®, Glad®, Brita®, RenewLife®, Ever Clean® and Burt’s Bees® brands.
19

RECENT EVENTS RELATED TO COVID-19
For our fiscal quarter ended March 31, 2022, the coronavirus (COVID-19) pandemic continued to cause economic and social disruptions that led to ongoing uncertainties. Demand for many of the products across the Company portfolio remained elevated compared to pre-pandemic levels. The Company expects a continuing inflationary environment heightened by the conflict in Ukraine, marked by higher manufacturing and logistics costs as well as increased commodity costs. While we have not experienced significant disruptions in our operations during fiscal year 2022 to date, risks of future negative impacts due to transportation, logistical or supply constraints and higher commodity costs for certain raw materials remain present. We are continuing to address these impacts to our operations.
We have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, consumers and communities, including taking precautionary measures, such as implementing contingency plans, making operational adjustments where necessary, and providing support to organizations that support front-line workers. As the U.S. and other countries have begun or are expected to begin to reopen their economies and the world moves into new phases of the pandemic, the Company will continue to focus on these priorities, while continuing to strive to serve people as consumer behaviors evolve inside and outside the home.
The extent of COVID-19’s effect on the Company’s operational and financial performance in the future will depend on future developments, including the duration, spread, intensity and phase of the pandemic in different countries, the emergence of COVID-19 variants and the effectiveness of vaccines against these variants, the Company’s continued ability to manufacture and distribute its products, any future government actions affecting consumers, our business operations, including any vaccine mandates, or the economy in general, and effectiveness of global vaccines, all of which are uncertain and difficult to predict considering the rapidly evolving landscape as the Company continues to expect a variable operating environment going forward.
For additional information on the impacts and our response to the coronavirus pandemic, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
20

RESULTS OF OPERATIONS
CONSOLIDATED RESULTS

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Net sales | $ | 1,809 |  |  | $ | 1,781 |  |  | 2 | % |  | $ | 5,306 |  |  | $ | 5,539 |  |  | (4) | %

| Three Months Ended March 31, 2022
| Percentage change versus the year-ago period
| Reported (GAAP) Net Sales Growth / (Decrease) | Reported Volume |  | Acquisitions & Divestitures | Foreign Exchange Impact | Price/Mix/ Other (1) | Organic Sales Growth / (Decrease) (Non-GAAP) (2) | Organic Volume (3)
Health and Wellness | (3) | % | 1 | % |  | — | % | — | % | (4) | % | (3) | % | 1 | %
Household | 6 |  | 2 |  |  | — |  | — |  | 4 |  | 6 |  | 2 |
Lifestyle | 4 |  | 6 |  |  | — |  | — |  | (2) |  | 4 |  | 6 |
International | 1 |  | 2 |  |  | — |  | (5) |  | 4 |  | 6 |  | 2 |
Total | 2 | % | 2 | % |  | — | % | — | % | — | % | 2 | % | 2 | %
| Nine Months Ended March 31, 2022
| Percentage change versus the year-ago period
| Reported (GAAP) Net Sales Growth / (Decrease) | Reported Volume |  | Acquisitions & Divestitures | Foreign Exchange Impact | Price/Mix/Other (1) | Organic Sales Growth / (Decrease) (Non-GAAP) (2) | Organic Volume (3)
Health and Wellness | (11) | % | (6) | % |  | — | % | — | % | (5) | % | (11) | % | (6) | %
Household | (1) |  | (2) |  |  | — |  | — |  | 1 |  | (1) |  | (2) |
Lifestyle | 4 |  | 4 |  |  | — |  | — |  | — |  | 4 |  | 4 |
International | 1 |  | (1) |  |  | — |  | (3) |  | 5 |  | 4 |  | (1) |
Total | (4) | % | (3) | % |  | — | % | — | % | (1) | % | (4) | % | (3) | %

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(2) Organic sales growth/ (decrease) is defined as net sales growth/ (decrease) excluding the effect of any acquisitions and divestitures and foreign exchange rate changes. See “Non-GAAP Financial Information” below for reconciliation of organic sales growth/(decrease) to net sales growth/ (decrease), the most directly comparable GAAP financial information.
(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures.
Net sales and volume in the current three month period both increased by 2%, reflecting higher shipments across all reportable segments, primarily driven by the Lifestyle and Household reportable segments.
Net sales and volume in the current nine month period decreased by 4% and 3%, respectively, reflecting lower shipments primarily in the Health and Wellness reportable segment.
21

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Gross profit | $ | 649 |  |  | $ | 774 |  |  | (16) | % |  | $ | 1,877 |  |  | $ | 2,531 |  |  | (26) | %
Gross margin | 35.9 | % |  | 43.5 | % |  |  |  | 35.4 | % |  | 45.7 | % |  |

Gross margin decreased by 760 basis points in the current three month period from 43.5% to 35.9%. The decrease was primarily driven by higher manufacturing and logistics costs and unfavorable commodity costs, partially offset by the benefit of price increases and cost savings.
Gross margin decreased by 1030 basis points in the current nine month period from 45.7% to 35.4%. The decrease was primarily driven by higher manufacturing and logistics costs and unfavorable commodity costs.
Expenses

| Three Months Ended
|  |  |  |  |  |  | % of Net Sales
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021
Selling and administrative expenses | $ | 233 |  |  | $ | 237 |  |  | (2) | % |  | 12.9 | % |  | 13.3 | %
Advertising costs | 153 |  |  | 200 |  |  | (24) |  |  | 8.5 |  |  | 11.2 |
Research and development costs | 31 |  |  | 32 |  |  | (3) |  |  | 1.7 |  |  | 1.8 |
| Nine Months Ended
|  |  |  |  |  |  | % of Net Sales
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021
Selling and administrative expenses | $ | 710 |  |  | $ | 744 |  |  | (5) | % |  | 13.4 | % |  | 13.4 | %
Advertising costs | 502 |  |  | 566 |  |  | (11) |  |  | 9.5 |  |  | 10.2 |
Research and development costs | 98 |  |  | 104 |  |  | (6) |  |  | 1.8 |  |  | 1.9 |

Selling and administrative expenses, as a percentage of net sales, decreased by 40 basis points in the current three month period and were essentially flat in the current nine month period compared to the prior period. The dollar decrease in the current nine month period in selling and administrative expenses was primarily due to lower incentive compensation expenses and the benefit from cost savings, partially offset by the Company’s digital capabilities and productivity enhancements investments.
Advertising costs, as a percentage of net sales, decreased by 270 basis points and 70 basis points in the current three and nine month periods, respectively. The dollar decrease in the current three month period in advertising costs was primarily due to the timing of spending. The dollar decrease in the current nine month period in advertising costs was primarily due to lower advertising spending. The Company’s U.S. retail advertising spend as a percentage of net sales was 9% and 12% in the current and prior three month periods, respectively.
Research and development costs, as a percentage of net sales, were essentially flat in the current three and nine month periods as compared to the prior periods. The Company continues to invest behind product innovation and cost savings.
22

Goodwill, trademark and other asset impairments, Interest expense, Other (income) expense, net, and the effective tax rate on earnings

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Goodwill, trademark and other asset impairments | $ | — |  |  | $ | 329 |  |  | $ | — |  |  | $ | 329 |
Interest expense | 21 |  |  | 25 |  |  | 69 |  |  | 74 |
Other (income) expense, net | 11 |  |  | 10 |  |  | 20 |  |  | (85) |
Effective tax rate on earnings (losses) | 23.9 | % |  | (1.4) | % |  | 23.3 | % |  | 22.5 | %

Goodwill, trademark and other asset impairments of $329 in the prior three and nine month periods reflected noncash impairment charges related to goodwill, trademarks, and other assets held by the VMS business (included within the Health and Wellness segment). See Notes to Condensed Consolidated Financial Statements for further information regarding the impairments recorded.
Other (income) expense, net was $11 and $10 in the current and prior three month periods, respectively, and $20 and ($85) in the current and prior nine month periods, respectively. The variance between the current and prior nine month periods was primarily due to the one-time, noncash remeasurement gain from the Company’s previously held equity interest in the Kingdom of Saudi Arabia (Saudi joint venture) in the prior period.
The effective tax rate on earnings (losses) was 23.9% and 23.3% for the current three and nine month periods, respectively, and (1.4)% and 22.5% for the prior three and nine month periods, respectively. The substantially lower tax rate on losses before income taxes in the prior three month period was driven by the partial non-deductibility of impaired VMS goodwill.
Diluted net earnings (losses) per share

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Diluted net earnings (losses) per share | $ | 1.21 |  |  | $ | (0.49) |  |  | 347 | % |  | $ | 2.91 |  |  | $ | 4.78 |  |  | (39) | %

Diluted net earnings (losses) per share (EPS) increased by $1.70, or 347%, in the current three month period, primarily due to the noncash impairment charges on assets held by the VMS business in the prior period, as well as lower advertising spending and higher net sales, partially offset by lower gross margin all in the current period.
Diluted net EPS decreased by $1.87, or 39%, in the current nine month period, primarily due to lower gross margin, lower net sales and the one-time, noncash remeasurement gain recognized on the previously held equity interest in the Saudi joint venture in the prior period, partially offset by the noncash impairment charges on assets held by the VMS business in the prior period and lower advertising spending in the current period.
23

SEGMENT RESULTS
The following presents the results of the Company’s reportable segments and certain unallocated costs reflected in Corporate (see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):
Health and Wellness

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Net sales | $ | 662 |  |  | $ | 680 |  |  | (3) | % |  | $ | 2,055 |  |  | $ | 2,310 |  |  | (11) | %
Earnings (losses) before income taxes | 84 |  |  | (183) |  |  | 146 |  |  | 245 |  |  | 315 |  |  | (22) |

Volume and earnings (losses) before income taxes increased by 1% and 146%, respectively, and net sales decreased by 3% during the current three month period. The increase in volume was due to higher shipments in Cleaning driven by market share growth due to merchandising support, increased supply and innovation, partially offset by lower shipments primarily in the Professional Products portfolio due to the ongoing impacts of the COVID-19 pandemic. The variance between volume and net sales was primarily due to higher trade promotion spending and unfavorable mix, partially offset by the benefit of price increases. The increase in earnings (losses) before income taxes was primarily due to the noncash impairment charges on assets held by the VMS business in the prior period, partially offset by higher manufacturing and logistics costs and lower net sales all in the current period.
Volume, net sales and earnings before income taxes decreased by 6%, 11% and 22%, respectively, during the current nine month period. The volume and net sales decreases were primarily due to lower shipments in the Professional Products portfolio due to higher COVID-19 related demand in the prior period. The variance between volume and net sales was primarily due to unfavorable mix. The decrease in earnings before income taxes was primarily due to lower net sales, higher manufacturing and logistics costs and unfavorable commodity costs, partially offset by the noncash impairment charges on assets held by the VMS business in the prior period and lower advertising spending in the current period.
Household

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Net sales | $ | 539 |  |  | $ | 510 |  |  | 6 | % |  | $ | 1,404 |  |  | $ | 1,421 |  |  | (1) | %
Earnings before income taxes | 92 |  |  | 97 |  |  | (5) |  |  | 138 |  |  | 266 |  |  | (48) |

Volume and net sales increased by 2% and 6%, respectively, and earnings before income taxes decreased by 5% during the current three month period. The volume and net sales increases were primarily driven by higher shipments in Litter mainly due to innovation and continued growth in e-commerce channel in the current period, partially offset by lower shipments in Grilling due to higher demand in the prior period. The variance between volume and net sales was primarily due to the benefit of price increases. The decrease in earnings before income taxes was mainly due to unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by net sales growth and lower advertising spending.
Volume, net sales and earnings before income taxes decreased by 2%, 1% and 48%, during the current nine month period. The volume decrease was primarily driven by lower shipments in Grilling due to higher demand in the prior period. The variance between volume and net sales was primarily due to the benefit of price increases and lower trade promotion spending, partially offset by unfavorable mix. The decrease in earnings before income taxes was mainly due to unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by lower advertising spending and cost savings.
Lifestyle

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Net sales | $ | 306 |  |  | $ | 293 |  |  | 4 | % |  | $ | 961 |  |  | $ | 928 |  |  | 4 | %
Earnings before income taxes | 66 |  |  | 68 |  |  | (3) |  |  | 239 |  |  | 259 |  |  | (8) |

Volume and net sales increased by 6% and 4%, respectively, and earnings before income taxes decreased by 3% during the current three month period. The volume and net sales increases were primarily driven by higher shipments of Natural Personal Care products primarily due to strong consumption, innovation and expanded distribution. The variance between volume and net sales was mainly due to higher trade promotion spending and unfavorable mix, partially offset by the benefit of price
24

increases. The decrease in earnings before income taxes was primarily due to unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by lower advertising spending and net sales growth.
Both volume and net sales increased by 4% and earnings before income taxes decreased by 8%, during the current nine month period. The volume and net sales growth were primarily driven by higher shipments of Natural Personal Care products primarily due to strong consumption, innovation and expanded distribution, and higher shipments of Brita water-filtration products due to expanded distribution and merchandising support. The decrease in earnings before income taxes was primarily due to unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by net sales growth.
International

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Net sales | $ | 302 |  |  | $ | 298 |  |  | 1 | % |  | $ | 886 |  |  | $ | 880 |  |  | 1 | %
Earnings before income taxes | 31 |  |  | 30 |  |  | 3 |  |  | 80 |  |  | 184 |  |  | (57) |

Volume, net sales and earnings before income taxes increased by 2%, 1% and 3%, respectively, during the current three month period. Volume increased primarily driven by higher shipments from ongoing demand for cleaning, disinfecting and litter products.The increase in earnings before income taxes was primarily due to net sales growth, partially offset by unfavorable commodity costs.
Volume and earnings before income taxes decreased by 1% and 57%, respectively, and net sales increased by 1% during the current nine month period.The variance between volume and net sales was mainly due to the benefit of price increases, partially offset by the impact of unfavorable foreign currency exchange rates. The decrease in earnings before income taxes was primarily due to the one-time, noncash remeasurement gain recognized on the previously held equity interest in the Saudi joint venture recognized in the prior period, unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by net sales growth and cost savings all in the current period.
25

Argentina
Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the condensed consolidated statement of earnings. The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, economic recession, impacts of COVID-19 and temporary price controls. As of March 31, 2022 and June 30, 2021, the net asset position, excluding goodwill, of Clorox Argentina was $44 and $48, respectively. Of these net assets, cash balances were approximately $12 and $11 as of March 31, 2022 and June 30, 2021, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for the nine months ended March 31, 2022 and the fiscal year ended June 30, 2021.
For additional information on the impacts of, and our response to, the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Corporate
Corporate includes certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses.

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | % Change |  | 3/31/2022 |  | 3/31/2021 |  | % Change
Losses before income taxes | $ | (73) |  |  | $ | (71) |  |  | 3 | % |  | $ | (224) |  |  | $ | (225) |  |  | — | %

Losses before income taxes were essentially flat in the current three and nine month periods due to increased investments in the Company’s digital capabilities and productivity enhancements offset by lower employee incentive compensation expenses.
FINANCIAL POSITION AND LIQUIDITY
The Company’s financial condition and liquidity remained strong as of March 31, 2022. The following table summarizes cash activities:

| Nine Months Ended
| 3/31/2022 |  | 3/31/2021
Net cash provided by operations | $ | 451 |  |  | $ | 893 |
Net cash used for investing activities | (167) |  |  | (341) |
Net cash used for financing activities | (363) |  |  | (944) |

Operating Activities
Net cash provided by operations was $451 in the current nine month period, compared with $893 in the prior nine month period. The decrease was primarily driven by lower cash earnings and an increase in working capital (lower Accounts payable and accrued liabilities in the current year driven by lower spend and timing of payments and cash inflows from collections due to higher sales in the prior fiscal year, partially offset by higher inventory builds in the prior fiscal year to improve product availability). These decreases were partially offset by lower tax payments and lower employee incentive compensation payments in the current nine month period.
Payment Terms Extension and Supply Chain Financing
The Company initiated the extension of its payment terms with its suppliers in the second half of fiscal year 2020 in order to improve working capital as part of and to fund the IGNITE strategy and in keeping with evolving market practices. The Company’s current payment terms do not exceed 120 days in keeping with industry standards. The Company’s operating cash flows are directly impacted as a result of the extension of the payment terms with the suppliers.
26

As part of those ongoing efforts, the Company has arranged for a global financial institution to offer a voluntary supply chain finance (SCF) program for the benefit of the Company’s suppliers. Leveraging the Company’s credit rating, the SCF program enables suppliers to directly contract with the financial institution to receive payment from the financial institution prior to the payment terms between the Company and the supplier, by selling the Company’s payables to the financial institution. The participation in the program is at the sole discretion of the supplier and the Company has no economic interest in a supplier's decision to enter into the agreement and has no direct financial relationship with the financial institution, as it relates to the SCF program. Once a supplier elects to participate in the SCF program and reaches an agreement with the financial institution, the supplier elects which individual Company invoices to sell to the financial institution. The terms of the Company’s payment obligations are not impacted by a supplier’s participation in the program and as such, the SCF program has no direct impact on the Company’s balance sheets, cash flows or liquidity. No guarantees are provided by the Company or any of our subsidiaries under the SCF program. There would not be an expected material impact to the Company’s liquidity or capital resources if the financial institution or a supplier terminated the SCF arrangement.
All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable and accrued liabilities in the Consolidated Balance Sheets and the associated payments are included in operating activities within the Consolidated Statements of Cash Flows. As of March 31, 2022 and June 30, 2021, the amount due to suppliers participating in SCF and included in Accounts payable and accrued liabilities was $218 and $152, respectively. While the Company does not have direct access to information on, or influence over, which invoices a participating supplier elects to sell to the financial institution, the Company expects that the majority of these amounts have been sold to the financial institution.
Investing Activities
Net cash used for investing activities was $167 in the current nine month period, compared with $341 in the prior nine month period. The year-over-year decrease was mainly due to the acquisition of an additional interest in the Company’s Saudi joint venture in the prior nine month period and lower capital spending in the current nine month period.
Financing Activities
Net cash used for financing activities was $363 in the current nine month period, compared with $944 in the prior nine month period. The year-over-year decrease was mainly due to lower treasury stock purchases and net cash sourced from borrowings, partially offset by reduced proceeds from employee stock option exercises in the current nine month period.
Current period financing activities included repayment of $300 of the Company’s senior notes with an annual fixed interest rate of 3.80% that became due in November 2021 and were repaid using commercial paper borrowings.
Capital Resources and Liquidity
As of March 31, 2022, current liabilities exceed ed current assets by $774, primaril y due to $600 of the Company's senior notes with an annual fixed interest rate of 3.05% coming due for repayment in September 2022. These senior notes are expected to be repaid through net proceeds from new borrowings. In addition, the Company’s cash generated from operations has decreased recently primarily due to higher manufacturing and logistics costs and unfavorable commodity costs. The Company continues to take actions to address some of the effects of such cost increases, which include implementing price increases, driving cost savings, and optimizing the Company’s supply chain.
Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak and other geopolitical circumstances. Notwithstanding potential unforeseen adverse market conditions and as part of the Company’s regular assessment of its cash needs, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.
27

Credit Arrangements
On March 25, 2022, the Company entered into a new $1,200 revolving credit agreement (the Credit Agreement) that matures in March 2027. The Credit Agreement replaced a prior $1,200 revolving credit agreement (the prior Credit Agreement) in place since November 2019. The Credit Agreement also changed the interest rate benchmark used as a reference rate for certain borrowings under the Credit Agreement from the London Interbank Offered Rate (LIBOR) to the secured overnight financing rate (SOFR). The Company did not incur any termination fees or penalties in connection with entering the new Credit Agreement, which was considered a debt modification. There were no borrowings under either the new Credit Agreement or the prior Credit Agreement as of March 31, 2022 and June 30, 2021, respectively, and the Company believes that borrowings under the new Credit Agreement are and will continue to be available for general corporate purposes.
The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar non-cash charges and certain other items (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.
The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of March 31, 2022, and anticipates being in compliance with all restrictive covenants for the foreseeable future.
As of March 31, 2022, the Company maintained $34 of foreign and other credit lines, of which $2 was outstanding.
Stock Repurchases and Dividend Payments
As of March 31, 2022, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date. During the three months ended March 31, 2022 and 2021, the Company repurchased 0 and 1,648 thousand shares of common stock at a cost of $0 and $305, respectively. During the nine months ended March 31, 2022 and 2021, the Company repurchased 152 and 3,072 thousand shares of common stock at a cost of $25 and $605, respectively.
Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:

| Three Months Ended |  | Nine Months Ended
| 3/31/2022 |  | 3/31/2021 |  | 3/31/2022 |  | 3/31/2021
Dividends per share declared | $ | 1.16 |  |  | $ | 1.11 |  |  | $ | 3.48 |  |  | $ | 3.33 |  |
Total dividends paid | 143 |  |  | 140 |  |  | 428 |  |  | 420 |  |

CONTINGENCIES
See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.
28

RECENTLY ISSUED ACCOUNTING STANDARDS
See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.
NON-GAAP FINANCIAL MEASURES
The non-GAAP financial measures that are included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.
Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.
The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:

| Three Months Ended March 31, 2022
| Percentage change versus the year-ago period
| Health and Wellness |  | Household |  | Lifestyle |  | International |  | Total
Net sales growth / (decrease) (GAAP) | (3) | % |  | 6 | % |  | 4 | % |  | 1 | % |  | 2 | %
Add: Foreign Exchange | — |  |  | — |  |  | — |  |  | 5 |  |  | — |
Add/(Subtract): Divestitures/Acquisitions | — |  |  | — |  |  | — |  |  | — |  |  | — |
Organic sales growth / (decrease) (non-GAAP) | (3) | % |  | 6 | % |  | 4 | % |  | 6 | % |  | 2 | %
| Nine Months Ended March 31, 2022
| Percentage change versus the year-ago period
| Health and Wellness |  | Household |  | Lifestyle |  | International |  | Total
Net sales growth / (decrease) (GAAP) | (11) | % |  | (1) | % |  | 4 | % |  | 1 | % |  | (4) | %
Add: Foreign Exchange | — |  |  | — |  |  | — |  |  | 3 |  |  | — |
Add/(Subtract): Divestitures/Acquisitions | — |  |  | — |  |  | — |  |  | — |  |  | — |
Organic sales growth / (decrease) (non-GAAP) | (11) | % |  | (1) | % |  | 4 | % |  | 4 | % |  | (4) | %

29

Cautionary Statement
This Report, including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to:
•intense competition in the Company’s markets;
•the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
•the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems; on the demand for the Company’s products; and on worldwide, regional and local adverse economic conditions, including increased risk of inflation;
•volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services;
•risks related to supply chain issues and product shortages as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers;
•risks relating to the significant increase in demand for disinfecting and other products due to the COVID-19 pandemic continuing;
•dependence on key customers and risks related to customer consolidation and ordering patterns;
•risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions, especially at a time when a large number of the Company’s employees are working remotely and accessing its technology infrastructure remotely;
•the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
•risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, in particular the impairment charges relating to the carrying value of the Company’s Vitamins, Minerals and Supplements business; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;
•the Company’s ability to maintain its business reputation and the reputation of its brands and products;
•lower revenue, increased costs or reputational harm resulting from government actions and compliance with regulations, or any material costs imposed by changes in regulation;
•the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
30

•the operations of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, weather events or natural disasters, political instability or uncertainty, disease outbreaks or pandemics, such as COVID-19, and terrorism;
•risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; inflationary pressures, particularly in Argentina; impact of the United Kingdom’s exit from the European Union; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
•the impact of macroeconomic and geopolitical trends and events, including the unfolding situation in Ukraine and its regional and global ramifications and the effects of inflation;
•the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
•the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
•the ability of the Company to implement and generate cost savings and efficiencies, and successfully implement its business strategies;
•the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
•risks related to additional increases in the estimated fair value of Procter & Gamble Co.’s interest in the Glad business;
•the performance of strategic alliances and other business relationships;
•the Company’s ability to attract and retain key personnel;
•the impact of Environmental, Social, and Governance (ESG) issues, including those related to climate change and sustainability on our sales, operating costs or reputation;
•environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
•the Company’s ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the Company of third-party intellectual property rights;
•the effect of the Company’s indebtedness and credit rating on its business operations and financial results and the Company’s ability to access capital markets and other funding sources;
•the Company’s ability to pay and declare dividends or repurchase its stock in the future;
•the impacts of potential stockholder activism; and
•risks related to any litigation associated with the exclusive forum provision in the Company’s bylaws.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.
31

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have not been any material changes to the Company’s market risk since June 30, 2021. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.
Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
No change in the Company’s internal control over financial reporting occurred during the third fiscal quarter of the fiscal year ending June 30, 2022, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
32

PART II – OTHER INFORMATION
Item 1.A. Risk Factors
For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 and the information in “Cautionary Statement” included in this Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.
In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.
The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the third quarter of fiscal year 2022.

| [a] |  | [b] |  | [c] |  | [d]
Period | Total Number of Shares Purchased |  | Average Price Paid per Share (1) |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs
January 1 to 31, 2022 | — |  |  | $ | — |  |  | — |  |  | $993 million
February 1 to 28, 2022 | — |  |  | — |  |  | — |  |  | $993 million
March 1 to 31, 2022 | — |  |  | — |  |  | — |  |  | $993 million
Total | — |  |  | $ | — |  |  | — |  |  |

____________________
(1)Average price paid per share in the period includes commission.
33

Item 6. Exhibits
See Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
Exhibit No.

10.1 |  | Credit Agreement, dated as of March 25, 2022, among The Clorox Company, the lenders listed therein, JPMorgan Chase Bank, N.A., Citibank, N.A., and Wells Fargo Bank, National Association, as Administrative Agents, and JPMorgan Chase Bank, N.A., as Servicing Ag en t (filed as Exhibit 10.1 to the Current Report on Form 8-K, filed March 28, 2022, incorporated herein by reference).
31.1 |  | Certification by the Chief Executive Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Certification by the Chief Financial Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 |  | Certification by the Chief Executive Officer and Chief Financial Officer of the Company Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH |  | XBRL Taxonomy Extension Schema Document.
101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document.
101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

34

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | THE CLOROX COMPANY
|  | (Registrant)
DATE: May 2, 2022 | BY | /s/ Laura Peck
|  | Laura Peck Vice President – Chief Accounting Officer and Corporate Controller

35